Laekna Inc. Files Director List with HKEX

Reuters12-12
Laekna Inc. Files Director List with HKEX

Laekna Inc., a biopharmaceutical company listed on the Hong Kong Stock Exchange (stock code: 2105), has filed an updated list of directors and their roles. The Board is chaired by Dr. LU Chris Xiangyang, who also serves as Chief Executive Officer. Other executive directors include Ms. XIE Ling and Dr. GU Xiang-Ju Justin. The non-executive directors are Dr. WANG David Guowei and Mr. SUN Yuan. Independent non-executive directors comprise Dr. YIN Xudong, Dr. LI Min, and Mr. ZHOU Jian. Committee memberships are as follows: Dr. LU Chris Xiangyang chairs the Nomination and Corporate Governance Committee, with Ms. XIE Ling, Dr. LI Min, and Mr. ZHOU Jian as members. Mr. ZHOU Jian chairs the Audit Committee, joined by Dr. WANG David Guowei and Dr. LI Min as members. The Remuneration Committee is chaired by Dr. YIN Xudong, with Ms. XIE Ling and Mr. ZHOU Jian serving as members.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laekna Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251212-11954054), on December 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment